The Tem group is a international medical technology company with its headquarter in Basel (Switzerland). In addition to the headquarter, the Tem group includes two companies in Munich, development and production sites in the USA and in UK and several sales offices worldwide.
Tem Innovations GmbH deals with the development and production of ROTEM® point-of-care diagnostic equipment and reagents.
The Tem International GmbH handles the sales distribution, marketing and customer service. The global activities of both companies are coordinated from the global headquarter in Basel. Since its founding in 2000, the group now employs about 130 people worldwide.
In 40 countries a network of sales and service companies makes it possible to establish higher proximity to our clients all over the world. In Germany, France, Italy, Belgium, the Netherlands, the United Kingdom, the United States and Canada the distribution of the products take place with the help of a direct sales team. Worldwide, the Tem International GmbH collaborates with a variety of different distribution companies.
With the 4 business areas: ROTEM® diagnostic equipment, reagents / quality control, data solutions, and cuvettes / accessories, the company is well positioned and able to offer its customers an almost incomparable wide range of products with perfectly matched service and training services.
For the continuous improvement of all processes, the Tem group runs a full quality management system according to ISO 9001: 2008 and EN ISO 13485: 2003 + AC: 2009.
Our vision is to redefine bleeding control strategy and optimize transfusion management to significantly improve patient outcome and lower healthcare cost per episode.
Tem products set standards
“Targeted therapy stops the bleeding.” This key statement aimed at our customers, drives all innovation activities at Tem. Easy and failsafe user handling is ensured by continuous hardware and software improvements, embedded into our fully CE and FDA compliant development processes.The aim of the Tem group is to improve the success of treatment in the patient and to reduce the overall cost of treatment through accurate and fast diagnosis, targeted therapies and controls.
A worldwide network of clinical and research physicians as well as manufacturing partners constitute the core of our test assay development activities. Fast and efficient response to market needs are assured by high innovation standards, company-wide innovation process control and annual R&D spending.
From the beginning our company has had a very close cooperation with our customers and suppliers.
In the future, we will continue to develop these close relationships across the globe, as this is the foundation of our success.